A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 52, Issue 2, 2015, Pages 217-231

  Bauer, Yasmina ^a   Tedrow, John ^b   De Bernard, Simon ^c   Birker Robaczewska, Magdalena ^a   Gibson, Kevin F ^b   Guardela, Brenda Juan ^b,d   Hess, Patrick ^a   Klenk, Axel ^a   Lindell, Kathleen O ^b   Poirey, Sylvie ^a   Renault, Bé Rengère ^a   Rey, Markus ^a   Weber, Edgar ^a   Nayler, Oliver ^a   Kaminski, Naftali ^b,d  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c SA   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Biomarkers; Genomics; Lung fibrosis

Indexed keywords

COLLAGEN; HYDROXYPROLINE; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; BLEOMYCIN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; C6 GENE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CTHRC1 GENE; CTSE GENE; DISEASE SEVERITY; DOWN REGULATION; FEMALE; FHL2 GENE; FIBROSING ALVEOLITIS; GAL GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; GREM1 GENE; HISTIOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LCN2 GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MAST CELL; MICROARRAY ANALYSIS; MMP7 GENE; NELL1 GENE; NONHUMAN; PCSK1 GENE; PLA2G2A GENE; PNEUMONIA; RAT; RAT MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC2A5 GENE; TRANSLATION REGULATION; UPREGULATION; ANIMAL; DISEASE MODEL; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION; GENETICS; GENOMICS; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION; GENOMICS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PROTEIN BIOSYNTHESIS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84922227403     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0310OC     Document Type: Article

References (64)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
2. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-284.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
4. Borchers AT, Chang C, Keen CL, Gershwin ME. Idiopathic pulmonary fibrosis - an epidemiological and pathological review. Clin Rev Allergy Immunol 2010;40:117-134.
5. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-1040.
6. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010;35:496-504.
7. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-1370.
8. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myo fibroblast in focus. Chest 2007;132:1311-1321.
9. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009;2:103-121.
10. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-1961.
11. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 2009;4:e5134.
12. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011;63:783-794.
13. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;298:H1235-H1248.
14. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167-175.
15. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-6297.
16. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
17. Barlo NP, van Moorsel CH, van den Bosch JM, Grutters JC. Predicting prognosis in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:85-95.
18. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-440.
19. Prasse A, Muller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009;14:788-795.
20. Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG. Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res 2010;11:89.
21. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010;9:129-140.
22. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-382.
23. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006;173:769-776.
24. Usuki J, Fukuda Y. Evolution of three patterns of intra-alveolar fi brosis produced by bleomycin in rats. Pathol Int 1995;45:552-564.
25. Holmes D III, Bartholmai B, Karwoski R, Zavaletta V, Robb R. The lung tissue research consortium: An extensive open database containing histological, clinical, and radiological data to study chronic lung disease. Insight Journal 2006. Available from: http://insight-journal.com/browse/publication/109
26. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-447.
27. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. pp. 397-420.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
29. Lottaz C, Toedling J, Spang R. Annotation-based distance measures for patient subgroup discovery in clinical microarray studies. Bioinformatics 2007;23:2256-2264.
30. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, et al. Severity of lunginjury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandinE(2) production. Am J Pathol 2004;165:1663-1676.
31. Cigna N, Farrokhi Moshai E, Brayer S, Marchal-Somme J, Wemeau-Stervinou L, Fabre A, Mal H, Leseche G, Dehoux M, Soler P, et al. The hedgehog system machinery controls transforming growth factor-beta-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. Am J Pathol 2012;181:2126-2137.
32. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012;18:441-446.
33. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012;159:218-227.
34. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, Mishima M, Kitaichi M, Izumi T. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007;131:650-656.
35. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-229.
36. Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D, King TJ, Lancaster L, Sahn S, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760-1769.
37. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97.
38. Yang Y, Ye Y, Lin X, Wu K, Yu M. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line sra01/04. PLoS One 2013;8:e56837.
39. Hisatomi K, Mukae H, Sakamoto N, Ishimatsu Y, Kakugawa T, Hara S, Fujita H, Nakamichi S, Oku H, Urata Y, et al. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type i and heat shock protein 47 in A549 cells. BMC Pulm Med 2012;12:24.
40. Leri A, Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS ONE 2011;6:e28134.
41. Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, Jou I, Kook KH. Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 2010;51:3061-3066.
42. Noble PW, Richeldi L, Kaminski N. End of an era: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:4-5.
43. Costabel U, Bonella F. Treatment of pulmonary fibrosis: new substances and new interventions [article in German]. Der Internist 2011;52:1422-1428.
44. Cabrera S, Selman M, Lonzano-Bolanos A, Konishi K, Richards TJ, Kaminski N, Pardo A. Gene expression profiles reveal molecular mechanisms involved in the progression and resolution of bleomycin-induced lung fibrosis. Am J Lung Cell Mol Physiol 2013;304:L593-L601.
45. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, Burns L, Renteria L, Woods J, Chen L, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One 2013;8:e59348.
46. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D, Heller RA. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 2000;97:1778-1783.
47. Blaauboer ME, Emson CL, Verschuren L, van Erk M, Turner SM, Everts V, Hanemaaijer R, Stoop R. Novel combination of collagen dynamics analysis and transcriptional pro fi ling reveals fibrosis-relevant genes and pathways. Matrix Biol 2013;32:424-431.
48. Hunt L, Colby T, Weiler D, Sur S, Butterfield J. Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo Clin Proc 1992;67:941-948.
49. Pesci A, Bertorelli G, Gabrielli M, Olivieri D. Mast cells in fibrotic lung disorders. Chest 1993;103:989-996.
50. Cha S-I, Chang CS, Kim EK, Lee JW, Matthay MA, Golden JA, Elicker BM, Jones K, Collard HR, Wolters PJ. Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology 2012;61:98-106.
51. Andersson CK, Andersson-Sjöland A, Mori M, Hallgren O, Pardo A, Eriksson L, Bjermer L, Löfdahl C-G, Selman M, Westergren-Thorsson G, et al. Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. Respir Res 2011;12:139.
52. Brun J, Dieudonné F-X, Marty C, Müller J, Schüle R, Patĩo-Garća A, Lecanda F, Fromigué O, Marie PJ. Fhl2 silencing reduces WNT signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS ONE 2013;8:e55034.
53. Renger A, Zafiriou M-P, Noack C, Pavlova E, Becker A, Sharkova K, Bergmann MW, El-Armouche A, Zimmermann W-H, Zelarayán LC. The four and a half LIM-domain (FHL) 2 controls early cardiac cell commitment and expansion via regulating β-catenin-dependent transcription. Stem Cells 2013;31:928-940.
54. Yoshioka S, King ML, Ran S, Okuda H, MacLean JA, McAsey ME, Sugino N, Brard L, Watabe K, Hayashi K. WNT7A regulates tumor growth and progression in ovarian cancer through the Wnt/β-catenin pathway. Mol Cancer Res 2012;10:469-482.
55. Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S, Tarui H, Sasaki H. Cthrc1 selectively activates the planar cell polarity pathway of WNT signaling by stabilizing the WNT-receptor complex. Dev Cell 2008;15:23-36.
56. Kudryavtseva E, Forde TS, Pucker AD, Adarichev VA. Wnt signaling genes of murine chromosome 15 are involved in sex-affected pathways of inflammatory arthritis. Arthritis Rheum 2012;64:1057-1068.
57. Kami D, Shiojima I, Makino H, Matsumoto K, Takahashi Y, Ishii R, Naito AT, Toyoda M, Saito H, Watanabe M, et al. Gremlin enhances the determined path to cardiomyogenesis. PLoS ONE 2008;3:e2407.
58. Myllörniemi M, Vuorinen K, Pulkkinen V, Kankaanranta H, Aine T, Salmenkivi K, Keski-Oja J, Koli K, Kinnula V. Gremlin localization and expression levels partially differentiate idiopathic interstitial pneumonia severity and subtype. J Pathol 2008;214:456-463.
59. Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA, Gershwin ME. Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 2005;4:450-459.
60. Taooka Y, Maeda A, Hiyama K, Ishioka S, Yamakido M. Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 1997;156:260-265.
61. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-408.
62. Pyagay P. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 2005;96:261-268.
63. LeClair R, Lindner V. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor β signaling. Trends Cardiovasc Med 2007;17:202-205.
64. Wixler V, Hirner S, Muller JM, Gullotti L, Will C, Kirfel J, Gunther T, Schneider H, Bosserhoff A, Schorle H, et al. Deficiency in the LIM-only protein Fhl2 impairs skin wound healing. J Cell Biol 2007;177:163-172.